ecrin-mdr-crcClinical2018IPD Sharing (as of October 2021): YesAdenocarcinomaColorectal NeoplasmGastrointestinal NeoplasmsIntestinal DiseasesGastrointestinal DiseaseDigestive System DiseasesNeoplasmsIntestinal DiseaseGastrointestinal DiseasesRectal DiseasesColorectal NeoplasmsDigestive System DiseaseIntestinal NeoplasmsColonic DiseasesDigestive System NeoplasmsDigestive System NeoplasmAdenocarcinomaColorectal NeoplasmGastrointestinal NeoplasmsIntestinal DiseasesGastrointestinal DiseaseDigestive System DiseasesNeoplasmsIntestinal DiseaseGastrointestinal DiseasesRectal DiseasesColorectal NeoplasmsDigestive System DiseaseIntestinal NeoplasmsDigestive System NeoplasmsColonic DiseasesDigestive System NeoplasmInterventionalhttps://newmdr.ecrin.org/Study/2275568Cuba10Oxidative StressMetastatic colorectal CancerOcoxin ViusidAntioxidantNutritional supplementECRIN MDRActive, not recruitingfalseEvaluation of Ocoxin-Viusid in Metastatic Colorectal AdenocarcinomaThe research product, registered as a nutritional supplement (Ocoxin, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin-Viusid on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin-Viusid it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.2018-10-152275568NCT03559543